Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Price Performance Shares of Xenon Pharmaceuticals stock opened at $56.69 on Thursday.
The chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transaction value of $78,000 on March 13, 2026. This sale represented 16.63% of his direct common stock holdings prior to the transaction, reducing his direct position from 8,479 to 7,069 shares.
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Bamco Inc. NY reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ: XENE) by 46.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 30,000 shares of the biopharmaceutical company's stock after selling 26,000 shares during the quarter. Bamco Inc. NY's holdings in Xenon
Driehaus Capital Management increased its XENE stake by 369,577 shares in the fourth quarter; the estimated transaction value was $15.52 million. Meanwhile, the quarter-end position value rose by $36.03 million, reflecting both trading and price appreciation.
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded warrants were offered at a price of $56.9999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $747.5 million.
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but follow major news that has led investors to re-rate each stock.
